Grade 3a Follicular Lymphoma: Clinical Trials

22 trials for Grade 3a Follicular Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 6 active not recruiting, 6 recruiting. 19 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Completed 8, Recruiting 6, Active not recruiting 5
Phase 18Completed 6, Active not recruiting 2

Follow Grade 3a Follicular Lymphoma: new trials by email Literature Review of Grade 3a Follicular Lymphoma trials Research Report on Grade 3a Follicular Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Phase 2RecruitingUniversity of Washington302026-10-092026-10-15
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Pirtobrutinib, Mosunetuzumab, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
Phase 2RecruitingUniversity of Washington222025-11-172026-06-04
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma
Phase 2RecruitingUniversity of Washington202024-08-292026-08-27
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Zanubrutinib, Rituximab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma
Phase 2RecruitingChinese PLA General Hospital302024-07-102026-07-20
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Phase 2CompletedUniversity of Washington422022-03-232026-05-13
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
Phase 2RecruitingEmory University492021-09-032026-02-09
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Ibrutinib, Obinutuzumab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma
Phase 2Active not recruitingUniversity of California, Davis402021-02-242026-04-13
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1 / Phase 2Active not recruitingUniversity of Washington232020-12-022026-06-25
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
Acalabrutinib, Lenalidomide, Rituximab - Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
Phase 2RecruitingM.D. Anderson Cancer Center802020-07-162026-11-02
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Anti-OX40 Antibody BMS 986178, Laboratory Biomarker Analysis, Radiation Therapy - B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Phase 1CompletedRonald Levy142018-04-092024-12-11
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Phase 2Active not recruitingSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University292018-02-202026-08-18
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)732018-01-232026-07-08
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia
Phase 1 / Phase 2CompletedAlexey Danilov, MD242017-07-172023-08-08
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma
Phase 1Active not recruitingBeth Christian222017-02-212026-09-24
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Phase 1 / Phase 2CompletedDavid Bond, MD362017-02-142026-09-23
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Phase 1CompletedKami Maddocks22017-01-122019-07-30
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Lenalidomide, Obinutuzumab - Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma
Phase 2CompletedM.D. Anderson Cancer Center962016-12-062025-06-08
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101 - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
Phase 1 / Phase 2CompletedRobert Lowsky212016-11-072024-10-16
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma
Phase 2CompletedM.D. Anderson Cancer Center482016-04-112024-09-24
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center662014-05-272025-06-24

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Lymphoma, Follicular (19)  ·  Lymphoma, B-Cell, Marginal Zone (9)  ·  Lymphoma, Mantle-Cell (6)  ·  Lymphoma, B-Cell (4)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Burkitt Lymphoma (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Waldenstrom Macroglobulinemia (2)  ·  Anemia (1)  ·  Fatigue (1)  ·  Fever (1)  ·  Leukemia, Hairy Cell (1)  ·  Leukemia, Prolymphocytic, B-Cell (1)  ·  Lymphoproliferative Disorders (1)

Broader conditions

Hemic and Lymphatic Diseases (19)  ·  Immune System Diseases (19)  ·  Immunoproliferative Disorders (19)  ·  Lymphatic Diseases (19)  ·  Lymphoma (19)  ·  Neoplasms (19)  ·  Neoplasms by Histologic Type (19)  ·  Lymphoproliferative Disorders (18)  ·  Lymphoma, Non-Hodgkin (16)  ·  Lymphoma, B-Cell (6)  ·  Hematologic Diseases (5)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Chronic Disease (3)  ·  DNA Virus Infections (3)  ·  Disease Attributes (3)

Interventions

obinutuzumab (9)  ·  Lenalidomide (7)  ·  Magnetic Resonance Spectroscopy (6)  ·  ibrutinib (6)  ·  Rituximab (4)  ·  Biopsy (3)  ·  CT-P10 (3)  ·  Specimen Handling (3)  ·  acalabrutinib (3)  ·  venetoclax (3)  ·  Bendamustine Hydrochloride (2)  ·  Radiation (2)  ·  Radiotherapy (2)  ·  6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)  ·  Bortezomib (1)

Sponsors

University of Washington (5)  ·  M.D. Anderson Cancer Center (4)  ·  National Cancer Institute (NCI) (3)  ·  Alexey Danilov, MD (1)  ·  Beth Christian (1)  ·  Chinese PLA General Hospital (1)  ·  David Bond, MD (1)  ·  Emory University (1)  ·  Kami Maddocks (1)  ·  Robert Lowsky (1)  ·  Ronald Levy (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)  ·  University of California, Davis (1)

Countries

United States (21)  ·  Canada (1)  ·  China (1)  ·  Singapore (1)

Top investigators

Ajay Gopal (2)  ·  Loretta J Nastoupil (2)  ·  Mengyang Di, MD, PhD (2)  ·  Ronald Levy (2)  ·  Beth Christian, MD (1)  ·  Craig Okada, M.D. (1)  ·  David Bond, MD (1)  ·  Jonathon B Cohen, MD, MS (1)  ·  Joseph M Tuscano (1)  ·  Kami Maddocks, MD (1)  ·  Kristie A Blum (1)  ·  Loretta Nastoupil (1)  ·  Michael Khodadoust (1)  ·  Nancy L Bartlett (1)  ·  Paolo Strati (1)

Results publications

PMID 34780125, PMID 29074501, PMID 31174236, PMID 34196037, PMID 35135810, PMID 35787017, PMID 37939259, PMID 37985359, PMID 39161543, PMID 40517417, PMID 42600120

NIH funding

R35CA197353 (2), U10CA180821 (2), N01CM00032 (1), N01CM00099 (1), P30CA015083 (1), P30CA016058 (1), P30CA093373 (1), P30CA138292 (1), U10CA031946 (1), U10CA180888 (1)